Lab
Pacific Diagnostic Laboratories
Pacific Diagnostic Laboratories was paid $19.72M by Medicaid between Jan 2018 and Dec 2024, across 239 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 9.3% of everything it billed.
33Billing provider infoPACIFIC DIAGNOSTIC LABORATORIES
SANTA BARBARA, CA 93111
SANTA BARBARA, CA 93111
33aNPI1477602639assigned 01/09/2007
33bProvider typeClinical Medical Laboratory
28Total paid$19.72M
24GClaims1,777,913
24DCodes billed239
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#45 of 561
Median peer was paid$222K
This provider vs. median89×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 132,733 | $1.82M | |
| 2019 | 166,917 | $1.99M | |
| 2020 | 225,814 | $2.41M | |
| 2021 | 319,361 | $3.82M | |
| 2022 | 321,222 | $3.61M | |
| 2023 | 327,700 | $3.19M | |
| 2024incomplete | 284,166 | $2.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.3% | 29,439 | 26,302 | $1.84M |
| 80053 | Comprehensive metabolic panel | 4.7% | 139,092 | 127,750 | $936K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.7% | 49,094 | 48,527 | $932K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.7% | 80,214 | 78,516 | $926K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 4.6% | 41,477 | 40,917 | $913K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.3% | 29,659 | 26,940 | $847K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.3% | 29,527 | 26,436 | $840K |
| 86003 | 4.2% | 8,052 | 7,756 | $832K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.9% | 10,507 | 10,335 | $766K |
| 80061 | Lipid panel | 3.2% | 72,605 | 72,037 | $641K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.1% | 128,236 | 117,131 | $618K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.4% | 22,895 | 20,681 | $467K |
227 more codes
| 83036 | Hemoglobin; glycosylated (A1C) | 2.0% | 60,797 | $389K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.0% | 13,517 | $389K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.9% | 19,649 | $374K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 60,912 | $322K |
| 86481 | 1.6% | 5,468 | $313K | |
| 86235 | 1.2% | 4,396 | $242K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 11,769 | $203K |
| 84439 | <1% | 30,646 | $196K | |
| 83516 | <1% | 22,274 | $186K | |
| 82728 | <1% | 20,347 | $178K | |
| 87632 | <1% | 1,121 | $177K | |
| 83013 | <1% | 3,753 | $174K | |
| 87077 | <1% | 23,037 | $131K | |
| 86803 | <1% | 13,665 | $127K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,522 | $127K |
| 84403 | <1% | 6,951 | $123K | |
| 86592 | <1% | 36,038 | $122K | |
| 82746 | <1% | 12,464 | $115K | |
| 83550 | <1% | 21,100 | $110K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,217 | $106K |
| 87507 | <1% | 326 | $106K | |
| 87480 | <1% | 6,401 | $104K | |
| 87510 | <1% | 6,395 | $104K | |
| 87660 | <1% | 6,396 | $104K | |
| 86480 | <1% | 2,241 | $101K | |
| 85027 | <1% | 21,733 | $97K | |
| 83970 | <1% | 5,310 | $92K | |
| 81001 | <1% | 48,140 | $92K | |
| 83540 | <1% | 22,210 | $91K | |
| 84153 | <1% | 8,705 | $88K | |
| 87070 | <1% | 13,206 | $87K | |
| 82670 | <1% | 4,020 | $86K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,909 | $86K |
| 86787 | <1% | 8,282 | $86K | |
| 87186 | <1% | 15,763 | $85K | |
| 87081 | <1% | 16,246 | $85K | |
| 88342 | <1% | 1,712 | $84K | |
| 86038 | <1% | 9,570 | $83K | |
| 82785 | <1% | 6,274 | $81K | |
| 86696 | <1% | 5,416 | $80K | |
| 84481 | <1% | 6,899 | $79K | |
| 83880 | <1% | 3,864 | $76K | |
| 86140 | <1% | 22,125 | $73K | |
| 87340 | <1% | 8,886 | $71K | |
| 82607 | <1% | 10,980 | $71K | |
| 82784 | <1% | 9,174 | $70K | |
| 84270 | <1% | 4,368 | $69K | |
| 81513 | <1% | 657 | $69K | |
| 82570 | <1% | 22,752 | $66K | |
| 88141 | <1% | 5,461 | $56K | |
| 86160 | <1% | 3,146 | $53K | |
| 86695 | <1% | 5,240 | $53K | |
| 82043 | <1% | 17,351 | $52K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 958 | $48K |
| 85652 | <1% | 26,779 | $47K | |
| 86850 | <1% | 16,428 | $46K | |
| 86706 | <1% | 5,502 | $44K | |
| 80074 | <1% | 1,165 | $44K | |
| 88112 | <1% | 1,115 | $44K | |
| 86704 | <1% | 4,930 | $44K | |
| 83525 | <1% | 4,375 | $42K | |
| 83735 | <1% | 9,506 | $42K | |
| 86762 | <1% | 3,327 | $41K | |
| 85610 | <1% | 15,275 | $41K | |
| 82533 | <1% | 3,643 | $40K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 101 | $39K |
| 86376 | <1% | 3,550 | $39K | |
| 82378 | <1% | 3,364 | $39K | |
| 87536 | <1% | 774 | $39K | |
| 82274 | <1% | 2,928 | $38K | |
| 86800 | <1% | 3,294 | $38K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,896 | $38K |
| 86255 | <1% | 3,992 | $37K | |
| 88341 | <1% | 224 | $37K | |
| 85730 | <1% | 8,427 | $36K | |
| 82627 | <1% | 2,121 | $36K | |
| 86780 | <1% | 3,290 | $35K | |
| 83001 | <1% | 2,390 | $33K | |
| 83615 | <1% | 8,636 | $32K | |
| 86300 | <1% | 2,472 | $32K | |
| 82024 | <1% | 1,329 | $31K | |
| 84144 | <1% | 1,900 | $31K | |
| 86141 | <1% | 3,340 | $31K | |
| 80069 | <1% | 8,622 | $30K | |
| 87209 | <1% | 2,223 | $30K | |
| 87427 | <1% | 4,076 | $30K | |
| 86901 | <1% | 12,584 | $29K | |
| 84480 | <1% | 2,645 | $28K | |
| 99000 | <1% | 12,716 | $28K | |
| 80076 | <1% | 4,867 | $28K | |
| 86900 | <1% | 12,138 | $27K | |
| 86769 | <1% | 814 | $25K | |
| 82977 | <1% | 4,560 | $25K | |
| 86431 | <1% | 6,364 | $25K | |
| 84100 | <1% | 9,126 | $25K | |
| 87015 | <1% | 4,819 | $24K | |
| 83002 | <1% | 1,692 | $24K | |
| 85007 | <1% | 9,586 | $23K | |
| 83690 | <1% | 4,618 | $22K | |
| 84305 | <1% | 1,372 | $22K | |
| 86039 | <1% | 2,682 | $22K | |
| 86360 | <1% | 763 | $21K | |
| 86359 | <1% | 910 | $21K | |
| 87205 | <1% | 7,157 | $20K | |
| 84146 | <1% | 1,397 | $20K | |
| 88304 | <1% | 661 | $19K | |
| 80197 | <1% | 2,586 | $18K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 692 | $18K |
| 82550 | <1% | 4,684 | $18K | |
| 84156 | <1% | 8,363 | $16K | |
| 87045 | <1% | 2,249 | $15K | |
| 87481 | <1% | 594 | $15K | |
| 84134 | <1% | 1,601 | $15K | |
| 87177 | <1% | 2,193 | $15K | |
| 84165 | <1% | 2,745 | $15K | |
| 85046 | <1% | 4,682 | $15K | |
| 84681 | <1% | 1,099 | $14K | |
| 86334 | <1% | 1,518 | $13K | |
| 88307 | <1% | 95 | $13K | |
| 82105 | <1% | 1,386 | $13K | |
| 84550 | <1% | 4,635 | $13K | |
| 86200 | <1% | 2,146 | $12K | |
| 84450 | <1% | 3,022 | $12K | |
| 82150 | <1% | 2,586 | $12K | |
| 84460 | <1% | 2,930 | $12K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 93 | $11K |
| 86708 | <1% | 1,230 | $11K | |
| 87147 | <1% | 2,632 | $11K | |
| 84478 | <1% | 2,282 | $11K | |
| 83630 | <1% | 820 | $11K | |
| 86301 | <1% | 885 | $11K | |
| 86765 | <1% | 952 | $10K | |
| 81003 | <1% | 5,987 | $10K | |
| 80164 | <1% | 1,552 | $9K | |
| 84445 | <1% | 247 | $9K | |
| 87625 | <1% | 292 | $9K | |
| 82248 | <1% | 2,466 | $8K | |
| 86735 | <1% | 759 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 219 | $8K |
| 86147 | <1% | 439 | $8K | |
| 82951 | <1% | 689 | $8K | |
| 82950 | <1% | 1,747 | $7K | |
| 81025 | <1% | 1,089 | $7K | |
| 85379 | <1% | 1,203 | $7K | |
| 83090 | <1% | 567 | $6K | |
| 86304 | <1% | 582 | $6K | |
| 86364 | <1% | 315 | $6K | |
| 88312 | <1% | 208 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 150 | $6K |
| 87529 | <1% | 238 | $6K | |
| 83655 | <1% | 924 | $6K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 60 | $6K |
| 85060 | <1% | 458 | $6K | |
| 86258 | <1% | 263 | $6K | |
| 83721 | <1% | 916 | $5K | |
| 87324 | <1% | 830 | $5K | |
| 84166 | <1% | 685 | $5K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 185 | $5K |
| 87493 | <1% | 220 | $5K | |
| 87046 | <1% | 2,256 | $5K | |
| 85014 | <1% | 2,017 | $5K | |
| 85018 | <1% | 1,964 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 459 | $5K |
| 82947 | <1% | 1,411 | $4K | |
| 88185 | <1% | 12 | $4K | |
| 84436 | <1% | 993 | $4K | |
| 83014 | <1% | 1,408 | $4K | |
| 82140 | <1% | 492 | $4K | |
| 86694 | <1% | 359 | $4K | |
| 87581 | <1% | 107 | $4K | |
| 87102 | <1% | 841 | $4K | |
| 87329 | <1% | 516 | $4K | |
| 86335 | <1% | 445 | $4K | |
| 87328 | <1% | 479 | $4K | |
| 87486 | <1% | 106 | $4K | |
| 81015 | <1% | 1,672 | $4K | |
| 84154 | <1% | 312 | $3K | |
| 87449 | <1% | 424 | $3K | |
| 82565 | <1% | 1,183 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 49 | $2K |
| 86308 | <1% | 468 | $2K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,418 | $2K |
| 84702 | <1% | 157 | $2K | |
| 86677 | <1% | 156 | $2K | |
| 86355 | <1% | 78 | $2K | |
| 82465 | <1% | 590 | $2K | |
| 86146 | <1% | 83 | $2K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 45 | $2K |
| 86593 | <1% | 460 | $2K | |
| 86317 | <1% | 579 | $2K | |
| 84155 | <1% | 854 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,824 | $1K |
| 80178 | <1% | 473 | $1K | |
| 82077 | <1% | 91 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 666 | $977.63 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 625 | $970.02 |
| 82330 | <1% | 114 | $831.44 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,515 | $717.97 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 4,226 | $623.75 |
| 88189 | <1% | 12 | $623.10 | |
| 82232 | <1% | 89 | $530.54 | |
| 86036 | <1% | 14 | $506.10 | |
| 82172 | <1% | 42 | $473.40 | |
| 86357 | <1% | 25 | $452.70 | |
| 86015 | <1% | 50 | $438.14 | |
| 84145 | <1% | 38 | $435.60 | |
| 82652 | <1% | 28 | $418.00 | |
| 85045 | <1% | 97 | $409.57 | |
| 82310 | <1% | 151 | $409.11 | |
| 88184 | <1% | 12 | $379.62 | |
| 86381 | <1% | 20 | $356.30 | |
| 99199 | Unlisted special service, procedure or report | <1% | 858 | $301.04 |
| 88311 | <1% | 40 | $264.96 | |
| 82340 | <1% | 78 | $260.28 | |
| 86709 | <1% | 26 | $250.57 | |
| 86870 | <1% | 16 | $239.46 | |
| 83935 | <1% | 69 | $221.25 | |
| 84484 | <1% | 25 | $169.66 | |
| 84300 | <1% | 82 | $168.61 | |
| 80051 | <1% | 38 | $167.72 | |
| 82397 | <1% | 14 | $158.18 | |
| 82247 | <1% | 33 | $121.36 | |
| 87181 | <1% | 54 | $93.44 | |
| 80156 | <1% | 24 | $93.28 | |
| 87101 | <1% | 13 | $86.38 | |
| 84207 | <1% | 12 | $45.80 | |
| 84132 | <1% | 15 | $34.40 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMOORE, LISA (EXECUTIVE VICE PRESIDENT & COO)
| Provider | Location | Paid |
|---|---|---|
| Cottage Clinical Network, LLC | Santa Barbara, CA | $11.08M |
| Eagle Quest | Las Vegas, NV | $9.95M |
| Kanawha County Dental Health Council INC | Charleston, WV | $60K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.